Research programme: small molecule drug discovery program - Critical Outcome Technologies/Delmar Chemicals Inc.
Latest Information Update: 16 Jul 2016
Price : $50
At a glance
- Originator Critical Outcome Technologies; Delmar Chemicals
- Developer Critical Outcome Technologies
- Class Small molecules
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Canada
- 12 Sep 2012 Early research in Undefined indications in Canada (unspecified route)